Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cytokinetics (CYTK)

Cytokinetics (CYTK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,767,344
  • Shares Outstanding, K 118,014
  • Annual Sales, $ 7,530 K
  • Annual Income, $ -526,240 K
  • EBIT $ -525 M
  • EBITDA $ -513 M
  • 60-Month Beta 0.80
  • Price/Sales 765.92
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 56.60% ( +0.80%)
  • Historical Volatility 42.69%
  • IV Percentile 25%
  • IV Rank 9.97%
  • IV High 262.51% on 12/26/23
  • IV Low 33.79% on 06/03/24
  • Put/Call Vol Ratio 0.22
  • Today's Volume 132
  • Volume Avg (30-Day) 605
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 70,344
  • Open Int (30-Day) 83,929

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.24
  • Number of Estimates 10
  • High Estimate -0.59
  • Low Estimate -1.60
  • Prior Year -1.38
  • Growth Rate Est. (year over year) +10.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
45.66 +6.87%
on 12/19/24
52.84 -7.66%
on 11/27/24
-0.31 (-0.62%)
since 11/22/24
3-Month
45.66 +6.87%
on 12/19/24
59.39 -17.84%
on 11/11/24
-3.30 (-6.33%)
since 09/23/24
52-Week
43.53 +12.11%
on 12/26/23
110.25 -55.74%
on 01/08/24
+4.19 (+9.41%)
since 12/22/23

Most Recent Stories

More News
Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

CYTK : 48.54 (-0.68%)
Why Cytokinetics Stock Was a Nearly 5% Winner Today

California-based biotech Cytokinetcs (NASDAQ: CYTK) finished the trading week in style, as its stock price outperformed many other titles by rising nearly 5% on Friday. News of a fresh licensing deal in...

CYTK : 48.54 (-0.68%)
SNY : 47.90 (+0.40%)
Cytokinetics Announces Sanofi's Acquisition of Aficamten Development Rights for Greater China

Sanofi will acquire exclusive rights to aficamten for treating hypertrophic cardiomyopathy in Greater China from Corxel Pharmaceuticals.Quiver AI SummaryCytokinetics, Inc. announced that Sanofi will acquire...

CYTK : 48.54 (-0.68%)
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China

CYTK : 48.54 (-0.68%)
Insider Sale: EVP Research & Development of $CYTK (CYTK) Sells 5,300 Shares

Fady Ibraham Malik, the EVP Research & Development of $CYTK ($CYTK), sold 5,300 shares of the company on 12-10-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...

CYTK : 48.54 (-0.68%)
Cytokinetics Initiates Confirmatory Study on Heart Failure Drug

Cytokinetics, Incorporated CYTK announced that the late-stage COMET-HF study on pipeline candidate, omecamtiv mecarbil, has started.COMET-HF (Confirmation of Omecamtiv Mecarbil Efficacy Trial in Heart...

BAYRY : 4.9000 (-0.20%)
CYTK : 48.54 (-0.68%)
CSTL : 27.31 (-0.80%)
SPRO : 0.9674 (+1.29%)
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CYTK : 48.54 (-0.68%)
FDA Accepts Cytokinetics' Application for Cardiovascular Drug

Cytokinetics, Incorporated CYTK announced that the FDA has accepted the company’s new drug application (NDA) for lead pipeline candidate, aficamten.Aficamten is a next-in-class cardiac myosin inhibitor....

BAYRY : 4.9000 (-0.20%)
CYTK : 48.54 (-0.68%)
CSTL : 27.31 (-0.80%)
SPRO : 0.9674 (+1.29%)
Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction

CYTK : 48.54 (-0.68%)
Insider Sale: President & CEO of $CYTK (CYTK) Sells 5,000 Shares

Robert I Blum, the President & CEO of $CYTK ($CYTK), sold 5,000 shares of the company on 12-02-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 1.2% of their...

CYTK : 48.54 (-0.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology...

See More

Key Turning Points

3rd Resistance Point 53.98
2nd Resistance Point 52.15
1st Resistance Point 50.51
Last Price 48.54
1st Support Level 47.04
2nd Support Level 45.21
3rd Support Level 43.57

See More

52-Week High 110.25
Fibonacci 61.8% 84.76
Fibonacci 50% 76.89
Fibonacci 38.2% 69.01
Last Price 48.54
52-Week Low 43.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar